Document is current
Any future updates will be listed below
-
Authors
Suzuki, Yasuhiro https://orcid.org/0000-0002-1108-4540
Yano, Takahiro
Suehiro, Youko
Iwasaki, Hiromi
Hidaka, Michihiro
Otsuka, Maki
Sunami, Kazutaka
Ikeda, Hirokazu
Sawamura, Morio
Ito, Takuo
Iida, Hiroatsu
Nagai, Hirokazu
- License Information
-
More Information
Article History
Received: 18 February 2020
Revised: 19 August 2020
Accepted: 25 August 2020
First Online: 4 September 2020
Compliance with ethical standards
:
: Hirokazu Nagai has received research funding from Janssen Pharmaceutical K. K., Celgene Corporation, Mundipharma K.K., Bayer Yakuhin Ltd., Abbvie G.K., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Esai Co., Ltd., Bristol-Myers Squibb, Ono Pharmaceutical Co., Ltd., Gilead Sciences Inc., Zenyaku Kogyo Co., Ltd., Solasia Pharma K.K, HUYA Bioscience International, AstraZeneca plc., SymBio Pharmaceuticals Ltd., Otsuka Pharmaceuticals Co., Ltd., and IQVIA serice Japan K.K., and honoraria from Janssen Pharmaceutical K. K., Celgene Corporation, Mundipharma K.K., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Esai Co., Ltd., Bristol-Myers Squibb, Ono Pharmaceutical Co., Ltd., Gilead Sciences Inc., Zenyaku Kogyo Co., Ltd., AstraZeneca plc., SymBio Pharmaceuticals Ltd., Roche Ltd., and Sanofi K.K. outside the submitted work; Kazutaka Sunami has received research funding from Novartis, GlaxoSmithKline, Janssen Pharmaceutical, Abbvie, Takeda Pharmaceutical, Sanofi, Bristol-Myers Squibb, Ono Pharmaceutical, MSD, Alexion Pharma, Daiichi Sankyo, and Celgene Corporation, and honoraria from Takeda Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical, and Celgene Corporation outside the submitted work.
